MedTrace Logo

Phase I Double-blind, Placebo-controlled Study of AZD7442

NCT04896541 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-06-27

No results posted yet for this study

Summary

AZD7442 mAbs are being evaluated for administration to prevent or treat COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD7442.

Conditions

Interventions

BIOLOGICAL

AZD7442 300 mg IM(male)

Single dose of 300 mg of AZD7442 or saline placebo on Day 1.

BIOLOGICAL

AZD7442 600 mg IM (male)

Single dose of 600 mg of AZD7442 or saline placebo on Day 1.

BIOLOGICAL

AZD7442 300 mg IV (male and female)

Single dose of 300 mg of AZD7442 or saline placebo on Day 1.

BIOLOGICAL

AZD7442 1000 mg IV (male)

Single dose 1000 mg of AZD7442 or saline placebo on Day 1.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2022-06-14
Completion
2022-06-14

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04896541 on ClinicalTrials.gov